Do these two new drugs (lecanemab and donanemab) work the same way aducanemab does? Does that mean that the aducanemab results weren't a fluke and that the amyloid plaque hypothesis may in fact be true?
It will be exciting to see how efficacious these amyloid-beta antibodies can become and there is also clearly a small mystery (or at least a lack of consensus) in why the newer drugs show efficacy and the previous ones all failed.